Literature DB >> 17017408

Leprosy blindness in Nepal.

Himanshu Ravi Gupta1, Suraj Shakya, Mahesh Shah, Heera Mana Pradhan.   

Abstract

Leprosy is a systemic disease with highest incidence of ocular complications and one of the important causes of blindness in the world. A comparative cross-sectional study was carried out to see the ocular involvement in leprosy leading to blindness in two groups of patients, one with the active disease and second already cured and thus released from treatment (RFT). Active cases attending Anandaban leprosy clinic, Patan hospital and RFT cases from Khokana leprosarium were included in the study consecutively. Total of 70 active cases and 101 RFT cases were evaluated during the study period. Active group of patients showed more of multibacillary type of disease than in RFT group. The prevalence of ocular manifestations was seen much higher among RFT cases accounting for 66.3% in contrast to active group where only 14.3% had ocular problems. Blindness was frequently seen in multibacillary (MB) leprosy patients in compare to paucibacillary (PB) disease in both the groups. However blindness frequency was seen more often among RFT cases accounting for 24% in compare to only 2.9% among active group. Causes of blindness were mainly corneal and cataract related disorders. Risk of blindness also increased with the increase in duration of illness. RFT group of leprosy patients are at higher risk of developing blindness than the active group thus eye care services should be more focused for this group. Having multibacillary type of disease could also be a risk for development of blindness.

Entities:  

Mesh:

Year:  2006        PMID: 17017408

Source DB:  PubMed          Journal:  Nepal Med Coll J        ISSN: 2676-1319


  2 in total

1.  Ocular complications of leprosy in yemen.

Authors:  Raga A A Salem
Journal:  Sultan Qaboos Univ Med J       Date:  2012-11-20

2.  Ocular leprosy in institutionalized Nigerian patients.

Authors:  J A Ebeigbe; F Kio
Journal:  Ghana Med J       Date:  2011-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.